Risks and benefits of TIPS in HCC and other liver malignancies: a literature review

BMC Gastroenterol. 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0.

Abstract

Background: Transjugular intrahepatic portosystemic shunt (TIPS) is a well-validated treatment option for clinically significant portal hypertension (CSPH) in the context of liver cirrhosis. Its high efficacy and safety in the management of treatment-refractory ascites and variceal bleeding have been extensively proven. Contraindications for TIPS include severe right heart failure, hepatic encephalopathy, and sepsis. However, the role of liver malignancy in TIPS is debatable. Mostly, primary liver malignancies such as hepatocellular carcinoma (HCC) emerge from advanced liver diseases. Coexisting portal hypertension in HCC often results in limited treatment options and a poor prognosis. Previous studies have shown that TIPS implantation in patients with HCC is technically feasible and is usually not associated with major adverse events. Furthermore, TIPS may help in bridging the time to liver transplantation in early HCC and allow for locoregional treatment in advanced HCC. However, several studies suggest that seeding tumour cells to the lungs by TIPS placement might worsen the prognosis.

Conclusions: TIPS placement in patients with coexisting liver malignancy remains a case-by-case decision, and there is no profound evidence allowing general recommendations. This review aims to provide a state-of-the-art overview of the potential risks and benefits of TIPS placement in patients with liver malignancies.

Keywords: Clinically significant portal Hypertension (CSPH); Hepatocellular carcinoma (HCC); Liver Cirrhosis; Liver metastases; Transjugular intrahepatic portosystemic shunt (TIPS).

Publication types

  • Review

MeSH terms

  • Ascites / etiology
  • Carcinoma, Hepatocellular* / complications
  • Carcinoma, Hepatocellular* / surgery
  • Esophageal and Gastric Varices* / complications
  • Gastrointestinal Hemorrhage / complications
  • Gastrointestinal Hemorrhage / therapy
  • Humans
  • Hypertension, Portal* / complications
  • Liver Cirrhosis / complications
  • Liver Neoplasms* / complications
  • Liver Neoplasms* / surgery
  • Portasystemic Shunt, Transjugular Intrahepatic* / adverse effects
  • Portasystemic Shunt, Transjugular Intrahepatic* / methods
  • Risk Assessment
  • Treatment Outcome